| 72.86 0 (0%) | 02-20 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 85.32 | 1-year : | 99.66 |
| Resists | First : | 73.05 | Second : | 85.32 |
| Pivot price | 72.83  |
|||
| Supports | First : | 72.65 |
Second : | 72.4 |
| MAs | MA(5) : | 72.85 |
MA(20) : | 72.77 |
| MA(100) : | 66.89 |
MA(250) : | 47.35 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 68.3 |
D(3) : | 68.7 |
| RSI | RSI(14): 63.6 | |||
| 52-week | High : | 73.05 | Low : | 21.51 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ RNA ] has closed below upper band by 44.0%. Bollinger Bands are 94.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 65 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 73.13 - 73.53 | 73.53 - 73.86 |
| Low: | 71.45 - 72.04 | 72.04 - 72.52 |
| Close: | 72 - 72.87 | 72.87 - 73.57 |
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Thu, 19 Feb 2026
Assetmark Inc. Buys 21,507 Shares of Avidity Biosciences, Inc. $RNA - MarketBeat
Wed, 18 Feb 2026
Avidity Biosciences Reports Del-desiran Clinical Trial Results - Intellectia AI
Mon, 16 Feb 2026
Avidity Biosciences, Inc. (RNA) Stock Analysis: Exploring Growth Potential In RNA Therapeutics - DirectorsTalk Interviews
Tue, 10 Feb 2026
Avidity Biosciences, Inc. $RNA Shares Acquired by Candriam S.C.A. - MarketBeat
Mon, 02 Feb 2026
Avidity Biosciences Announces Expected Record Date for Spin-Off - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 151 (M) |
| Held by Insiders | 1.2851e+008 (%) |
| Held by Institutions | 4 (%) |
| Shares Short | 9,740 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -6.0906e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 513.4 % |
| Return on Equity (ttm) | -20.3 % |
| Qtrly Rev. Growth | 2.087e+007 % |
| Gross Profit (p.s.) | 452.08 |
| Sales Per Share | -33.8 |
| EBITDA (p.s.) | -4.86792e+008 |
| Qtrly Earnings Growth | -4.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -581 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -2.16 |
| Price to Cash Flow | 5.44 |
| Dividend | 0 |
| Forward Dividend | 8.41e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|